$IMUX
Immunic Inc

2020 Form 10-K Financial Statement

#000128077621000009 Filed on February 26, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.33M $2.160M $2.080M
YoY Change -28.86% -14.62% -15.45%
% of Gross Profit
Research & Development $38.64M $6.030M $7.102M
YoY Change 71.63% 3920.0% 403.69%
% of Gross Profit
Depreciation & Amortization $39.00K $10.00K $9.000K
YoY Change -22.0% -90.0% -95.59%
% of Gross Profit
Operating Expenses $48.97M $8.186M $9.177M
YoY Change 32.24% 56.4% 408.42%
Operating Profit -$48.97M -$9.177M
YoY Change 32.24% 408.42%
Interest Expense $60.00K $20.00K $60.00K
YoY Change -45.45% -75.0% -45.45%
% of Operating Profit
Other Income/Expense, Net $4.954M $480.0K $962.0K
YoY Change 136.02% 4700.0% 11925.0%
Pretax Income -$44.02M -$7.690M -$8.220M
YoY Change 26.02% 212.6% -31.16%
Income Tax
% Of Pretax Income
Net Earnings -$44.02M -$7.691M -$8.215M
YoY Change 26.0% 59.83% 357.15%
Net Earnings / Revenue
Basic Earnings Per Share -$2.81
Diluted Earnings Per Share -$2.81 -$750.2K -$820.4K
COMMON SHARES
Basic Shares Outstanding 15.66M shares 10.12M shares 10.09M shares
Diluted Shares Outstanding 15.66M shares

Balance Sheet

Concept 2020 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.5M $29.40M $30.50M
YoY Change 333.67% 121.05% 71.35%
Cash & Equivalents $127.5M $29.37M $30.50M
Short-Term Investments
Other Short-Term Assets $6.000M $796.0K $4.100M
YoY Change 106.9% 1070.59% 215.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $133.7M $32.23M $34.52M
YoY Change 315.22% 141.77% 81.1%
LONG-TERM ASSETS
Property, Plant & Equipment $1.100M $80.00K $44.00K
YoY Change 57.14% 100.0% -95.06%
Goodwill $32.97M $32.97M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $42.00K
YoY Change
Total Long-Term Assets $34.20M $33.73M $33.09M
YoY Change 1.18% 84212.5% 3469.04%
TOTAL ASSETS
Total Short-Term Assets $133.7M $32.23M $34.52M
Total Long-Term Assets $34.20M $33.73M $33.09M
Total Assets $167.9M $65.96M $67.60M
YoY Change 154.39% 393.27% 238.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.700M $2.423M $3.718M
YoY Change 54.17% 73.07% 228.74%
Accrued Expenses $4.300M $3.298M $3.236M
YoY Change 30.3% 692.79% -28.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.400M $7.072M $7.036M
YoY Change 18.31% 268.33% 23.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $500.0K $41.00K
YoY Change 40.0%
Total Long-Term Liabilities $700.0K $520.0K $41.00K
YoY Change 40.0% -8.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.400M $7.072M $7.036M
Total Long-Term Liabilities $700.0K $520.0K $41.00K
Total Liabilities $9.100M $7.592M $7.077M
YoY Change 19.74% 295.42% 23.38%
SHAREHOLDERS EQUITY
Retained Earnings -$59.90M -$52.00M
YoY Change 139.6% -84.48%
Common Stock $1.000K $1.000K
YoY Change -75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $158.8M $58.36M $60.53M
YoY Change
Total Liabilities & Shareholders Equity $167.9M $65.96M $67.60M
YoY Change 154.39% 393.27% 238.22%

Cashflow Statement

Concept 2020 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$44.02M -$7.691M -$8.215M
YoY Change 26.0% 59.83% 357.15%
Depreciation, Depletion And Amortization $39.00K $10.00K $9.000K
YoY Change -22.0% -90.0% -95.59%
Cash From Operating Activities -$46.12M -$6.270M -$5.980M
YoY Change 61.58% 34.55% -54.28%
INVESTING ACTIVITIES
Capital Expenditures $146.0K -$30.00K -$10.00K
YoY Change 165.45% -96.3%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $1.250M
YoY Change -100.0% -100.0%
Cash From Investing Activities -$146.0K -$20.00K $1.240M
YoY Change -101.39% -111.11% -559.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $144.4M 4.710M 220.0K
YoY Change 313.9% 1000.0%
NET CHANGE
Cash From Operating Activities -$46.12M -6.270M -5.980M
Cash From Investing Activities -$146.0K -20.00K 1.240M
Cash From Financing Activities $144.4M 4.710M 220.0K
Net Change In Cash $98.08M -1.580M -4.520M
YoY Change 501.85% -64.73% -66.09%
FREE CASH FLOW
Cash From Operating Activities -$46.12M -$6.270M -$5.980M
Capital Expenditures $146.0K -$30.00K -$10.00K
Free Cash Flow -$46.27M -$6.240M -$5.970M
YoY Change 61.78% 33.91% -53.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-36201
CY2020 dei Entity Registrant Name
EntityRegistrantName
Immunic, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2358443
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
1200 Avenue of the Americas,
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2020 dei City Area Code
CityAreaCode
332
CY2020 dei Local Phone Number
LocalPhoneNumber
255-9818
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2020 dei Trading Symbol
TradingSymbol
IMUX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
181400000 USD
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21168240 shares
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127452000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29369000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6293000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2861000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
133745000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
32230000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
203000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
32970000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
32970000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
901000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
633000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 USD
CY2020Q4 us-gaap Assets
Assets
167861000 USD
CY2019Q4 us-gaap Assets
Assets
65955000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3700000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2423000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4318000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
379000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1351000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8397000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7072000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
679000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
679000 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
520000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
9076000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
7592000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21168240 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21168240 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10744806 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10744806 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
266823000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119646000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4112000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1373000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103928000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59911000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
158785000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
58363000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
167861000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65955000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38637000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22512000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10334000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14520000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
48971000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
37032000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-48971000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-37032000 USD
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
58000 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
107000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4896000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1992000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4954000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2099000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44017000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.52
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15663826 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7722269 shares
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44017000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2739000 USD
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-554000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46756000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35487000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25741000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-554000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
529000 USD
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
37193000 USD
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
39400000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
58363000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44017000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2739000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2747000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
158785000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44017000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000 USD
CY2020 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0 USD
CY2019 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
329000 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
26000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2747000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6512000 USD
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2528000 USD
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1540000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2779000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2224000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1000000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-462000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1255000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1102000 USD
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
669000 USD
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
225000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46124000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28545000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000 USD
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
75000 USD
CY2020 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0 USD
CY2019 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
2475000 USD
CY2020 imux Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
0 USD
CY2019 imux Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
8151000 USD
CY2020 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2019 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
40000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10536000 USD
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
USD
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
270000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144431000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34895000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-78000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-589000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
98083000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16297000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29369000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13072000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127452000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29369000 USD
CY2020 imux Deferred Stock Issuance Costs Included In Liabilities
DeferredStockIssuanceCostsIncludedInLiabilities
0 USD
CY2019 imux Deferred Stock Issuance Costs Included In Liabilities
DeferredStockIssuanceCostsIncludedInLiabilities
20000 USD
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
37193000 USD
CY2020 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
0 USD
CY2019 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
39400000 USD
CY2020 imux Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
114000 USD
CY2019 imux Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
0 USD
CY2020 imux Property Plant And Equipment Included In Accounts Payable
PropertyPlantAndEquipmentIncludedInAccountsPayable
0 USD
CY2019 imux Property Plant And Equipment Included In Accounts Payable
PropertyPlantAndEquipmentIncludedInAccountsPayable
19000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103900000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59900000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
216800000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127500000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div>
CY2020 imux Cash Equivalents Investments Maturity Period
CashEquivalentsInvestmentsMaturityPeriod
P3M
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
39000 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
50000 USD
CY2019 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2020 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q4 imux Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
2 lease
CY2020Q4 imux Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
2 lease
CY2020Q4 imux Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
3416000 USD
CY2019Q4 imux Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
1307000 USD
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
295000 USD
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
408000 USD
CY2020Q4 imux Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
1348000 USD
CY2019Q4 imux Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
350000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1234000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
796000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6293000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2861000 USD
CY2020Q4 imux Clinical Costs Payable Current
ClinicalCostsPayableCurrent
3408000 USD
CY2019Q4 imux Clinical Costs Payable Current
ClinicalCostsPayableCurrent
1981000 USD
CY2020Q4 imux Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
139000 USD
CY2019Q4 imux Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
226000 USD
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
153000 USD
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
216000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3700000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2423000 USD
CY2020Q4 imux Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
3301000 USD
CY2019Q4 imux Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
2863000 USD
CY2020Q4 imux Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
114000 USD
CY2019Q4 imux Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
211000 USD
CY2020Q4 imux Accrued Compensation Current
AccruedCompensationCurrent
658000 USD
CY2019Q4 imux Accrued Compensation Current
AccruedCompensationCurrent
0 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4318000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298000 USD
CY2020Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
0 USD
CY2019Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
1008000 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
379000 USD
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
343000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
379000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1351000 USD
CY2020 imux Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
427000 USD
CY2020 imux Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
354000 USD
CY2019 imux Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
135000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
348000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
348000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
198000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
124000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
62000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1080000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
107000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
973000 USD
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
1200000 USD
CY2016Q2 imux Asset Purchase Agreement Royalties As Percent Of Aggregated Net Sales
AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
0.044
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120070 shares
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1500000 USD
CY2018Q2 imux Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000.0 USD
CY2020Q4 imux Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
250000000.0 shares
CY2020 imux Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock
ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
0.030
CY2019Q4 imux Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
34600000 USD
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156920 shares
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.00
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
846953 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.00
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3719.60
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2038195 shares
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7000000.0 USD
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M19D
CY2020 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-44017000 USD
CY2019 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-44759000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.030
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.033
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.019
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.030
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.203
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.202
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
17369000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
16357000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
125000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
18998000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
12237000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
30000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
72000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36522000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28666000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
311000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
311000 USD
CY2020Q4 imux Deferred Tax Assets And Liabilities Gross
DeferredTaxAssetsAndLiabilitiesGross
36517000 USD
CY2019Q4 imux Deferred Tax Assets And Liabilities Gross
DeferredTaxAssetsAndLiabilitiesGross
28355000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36517000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28355000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6800000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23700000 USD
CY2020Q4 imux Line Of Credit Facility Number Of Tranches
LineOfCreditFacilityNumberOfTranches
3 tranche
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44017000 USD
CY2020Q4 imux Line Of Credit Facility Tranche Payment Deferral Term
LineOfCreditFacilityTranchePaymentDeferralTerm
P5Y
CY2020Q4 imux Line Of Credit Facility Tranche Payment Deferral Term
LineOfCreditFacilityTranchePaymentDeferralTerm
P5Y
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
9014000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
12222000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
13545000 USD
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
14190000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
48971000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8487000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11458000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-12913000 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-11159000 USD
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4662000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
15007000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
9177000 USD
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
8186000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
37032000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4313000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14714000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-8215000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7691000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.09
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.52

Files In Submission

Name View Source Status
0001280776-21-000009-index-headers.html Edgar Link pending
0001280776-21-000009-index.html Edgar Link pending
0001280776-21-000009.txt Edgar Link pending
0001280776-21-000009-xbrl.zip Edgar Link pending
exhibit231.htm Edgar Link pending
exhibit42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imux-123120xexhibit211.htm Edgar Link pending
imux-123120xexhibit311.htm Edgar Link pending
imux-123120xexhibit312.htm Edgar Link pending
imux-123120xexhibit321.htm Edgar Link pending
imux-123120xexhibit322.htm Edgar Link pending
imux-20201231.htm Edgar Link pending
imux-20201231.xsd Edgar Link pending
imux-20201231_cal.xml Edgar Link unprocessable
imux-20201231_def.xml Edgar Link unprocessable
imux-20201231_g1.jpg Edgar Link pending
imux-20201231_htm.xml Edgar Link completed
imux-20201231_lab.xml Edgar Link unprocessable
imux-20201231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending